Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

102,803 14,401 117,204

TREANDA 24,551 - 24,551

Other 4,691 23,195 27,886

Oncology 29,242 23,195 52,437

Other 11,351 35,000 46,351

$396,938 $92,726 $489,664

Three Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $202,202 $14,904 217,106

GABITRIL 12,952 881 13,833

CNS 215,154 15,785 230,939

ACTIQ 45,946 10,007 55,953

Generic OTFC 32,689 - 32,689

FENTORA 33,193 - 33,193

AMRIX - - -

Pain 111,828 10,007 121,835

TREANDA - - -

Other 4,301 18,405 22,706

Oncology 4,301 18,405 22,706

Other 14,990 38,259 53,249

$346,273 $82,456 $428,729

%

Increase

(Decrease)

<
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
(Date:7/31/2014)... 2014 Senomyx , Inc. (NASDAQ: ... proprietary taste science technologies to discover, develop, and ... and ingredient supply industries, today reported financial results ... the second quarter with $33.6 million in cash ... the past quarter Senomyx achieved another important milestone ...
(Date:7/31/2014)... and SHENZHEN, China , July ... today the purchase of an Irys™System by ... selected BioNano,s platform to enable comprehensive exploration of human ... for various organisms of interest, including those where no ... together to develop new methods for multiplexing on the ...
(Date:7/31/2014)... Diego, CA (PRWEB) July 31, 2014 ... announced today the integration of Omicsoft’s Array Suite with ... both platforms will be able to send data in ... integration works with all versions of tranSMART including the ... the art statistics, visualization and storage for the analysis ...
Breaking Biology Technology:Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... May 25, 2011 Otonomy, Inc., ... for diseases and disorders of the inner and ... Wroblewski as the company,s chief operations officer.  Mr. ... the areas of manufacturing, product supply chain management, ...
... Lund, Sweden, researchers can study a wide range of different ... This could be useful for both basic research and industry ... DanishSwedish collaboration. Now it is opening for research. The ... is used to examine the components of materials and their ...
... Spherix Incorporated (NASDAQ: SPEXD) – an ... syndrome and atherosclerosis, and providers of technical and ... pharmaceutical companies – today announced that it has ... concerns minimum bid price listing requirements. ...
Cached Biology Technology:Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 2Otonomy Appoints Gerald Wroblewski as Chief Operations Officer 3New beamline at MAX II opens for research 2Spherix Regains Compliance With NASDAQ Listing Rule 2
(Date:7/31/2014)... available in German . ... gases similar to a sponge that soaks up liquids. ... hydrogen or greenhouse gases. However, loading of many MOFs ... Technology (KIT) now report in Nature Communications ... MOF surface. This can be prevented by water-free synthesis ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... found that bacteria in the Gulf of Mexico consumed ... during the Deepwater Horizon spill in the months after ... In two new studies conducted in a deep sea ... bacteria called Colwellia likely consumed gaseous hydrocarbons ... were released as part of the oil spill. ...
Breaking Biology News(10 mins):Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... in soils are as diverse in the tropical forests of Costa ... the tundra and boreal forests of Alaska and Sweden. That ... Proceedings of the National Academy of Sciences . Scientists ... found above ground at the equator than at the Earth,s poles. ...
... series are already enjoying the advantages of synthetic blood. While ... big screen, the true benefits of blood manufactured from embryonic ... It is unclear however whether society can develop an acceptance ... produced by related technology. For this reason it is ...
... WASHINGTON and LONDON On the heels of a ... D.C., leaders of the U.S. National Academy of Sciences and ... global insurance and reinsurance broker headquartered in the U.K., pledged ... financial resilience of populations to extreme events. Although 2011 ...
Cached Biology News:From tropics to poles: Study reveals diversity of life in soils 2Can we share vampires' appetite for synthetic blood? 2US science academy and global reinsurance broker spark 2US science academy and global reinsurance broker spark 3US science academy and global reinsurance broker spark 4
...
... HighSens reagents and supplies, for 10 ... sufficient to perform high-sensitivity RNA analysis ... the Experion automated electrophoresis system. Supplied ... microliters RNA HighSens stain, 20 microliters ...
... solid. PROTECT FROM LIGHT. PACKAGED UNDER ... that acts as a selective, reversible ... (IC 50 = 4 μM ... and PTP1B 298 , respectively). ...
...
Biology Products: